Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 249

1.

Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.

Eddy SF, Kane SE, Sonenshein GE.

Cancer Res. 2007 Oct 1;67(19):9018-23.

2.

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.

Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.

Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3.

3.

FOXO1A is a target for HER2-overexpressing breast tumors.

Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV.

Cancer Res. 2010 Jul 1;70(13):5475-85. doi: 10.1158/0008-5472.CAN-10-0176. Epub 2010 Jun 15.

5.

Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.

D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N.

Breast Cancer Res Treat. 2010 Sep;123(2):387-96. doi: 10.1007/s10549-009-0649-x. Epub 2009 Nov 28.

PMID:
19946741
8.

Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.

O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ.

Mol Cancer Ther. 2010 Jun;9(6):1489-502. doi: 10.1158/1535-7163.MCT-09-1171. Epub 2010 May 25. Erratum in: Mol Cancer Ther. 2011 Nov;10(11):2211.

9.

Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).

Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castilló B, Pérez-Martínez MC, Cufí S, Del Barco S, Bernado L, Brunet J, López-Bonet E, Menendez JA.

Int J Oncol. 2010 Sep;37(3):669-78.

PMID:
20664936
10.

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.

Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ.

Nat Clin Pract Oncol. 2006 May;3(5):269-80. Review.

PMID:
16683005
11.

Dual fatty acid synthase and HER2 signaling blockade shows marked antitumor activity against breast cancer models resistant to anti-HER2 drugs.

Blancafort A, Giró-Perafita A, Oliveras G, Palomeras S, Turrado C, Campuzano Ò, Carrión-Salip D, Massaguer A, Brugada R, Palafox M, Gómez-Miragaya J, González-Suárez E, Puig T.

PLoS One. 2015 Jun 24;10(6):e0131241. doi: 10.1371/journal.pone.0131241. eCollection 2015.

14.

Epigallocatechin-3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases.

Sah JF, Balasubramanian S, Eckert RL, Rorke EA.

J Biol Chem. 2004 Mar 26;279(13):12755-62. Epub 2003 Dec 29.

15.

Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.

Scaltriti M, Serra V, Normant E, Guzman M, Rodriguez O, Lim AR, Slocum KL, West KA, Rodriguez V, Prudkin L, Jimenez J, Aura C, Baselga J.

Mol Cancer Ther. 2011 May;10(5):817-24. doi: 10.1158/1535-7163.MCT-10-0966. Epub 2011 Mar 7.

17.

Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L.

Real PJ, Benito A, Cuevas J, Berciano MT, de Juan A, Coffer P, Gomez-Roman J, Lafarga M, Lopez-Vega JM, Fernandez-Luna JL.

Cancer Res. 2005 Sep 15;65(18):8151-7.

18.

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.

Nahta R, O'Regan RM.

Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015. Review.

PMID:
21115425
19.
20.

In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells.

Ozbay T, Durden DL, Liu T, O'Regan RM, Nahta R.

Cancer Chemother Pharmacol. 2010 Mar;65(4):697-706. doi: 10.1007/s00280-009-1075-9. Epub 2009 Jul 28.

Supplemental Content

Support Center